Survodutide, a dual glucagon/GLP-1 receptor agonist peptide, improved fatty liver disease (MASH) in up to 62% of patients compared to 14% on placebo in a 48-week trial.
62% vs 14%At the 4.8 mg dose, survodutide achieved histologic MASH improvement in 62% of patients compared to just 14% on placebo
What the researchers found
Survodutide achieved MASH improvement without fibrosis worsening in 47% (2.4 mg), 62% (4.8 mg), and 43% (6.0 mg) of participants vs 14% on placebo (P<0.001). Liver fat reduction ≥30% occurred in 57-67% of survodutide groups vs 14% placebo. Fibrosis improved by ≥1 stage in 34-36% vs 22% placebo.
Why it matters
MASH affects millions worldwide and has limited treatment options. Dual receptor agonism combining glucagon's fat-burning effects with GLP-1's metabolic benefits may offer a more powerful approach than GLP-1 alone, potentially changing how we treat this progressive liver disease.
The numbers in context
48-week trial. Adults with biopsy-confirmed MASH and fibrosis stage F1-F3. Randomized 1:1:1:1 to different doses vs. placebo.
How the study worked
Phase 2, randomized, double-blind, placebo-controlled trial. 293 adults with biopsy-confirmed MASH and fibrosis (F1-F3) randomized 1:1:1:1 to survodutide 2.4 mg, 4.8 mg, 6.0 mg, or placebo via weekly subcutaneous injection for 48 weeks (24-week dose escalation + 24-week maintenance). Primary endpoint: histologic MASH improvement without fibrosis worsening.
Who was studied
Adults with biopsy-confirmed MASH and fibrosis (F1-F3)
What this study cannot tell us
Phase 2 trial — still needs phase 3 confirmation with larger numbers. The 6.0 mg dose unexpectedly performed worse than 4.8 mg, possibly due to tolerability-driven dropouts. High rates of GI side effects (nausea 66%, diarrhea 49%, vomiting 41%). 48-week duration may not capture long-term safety or sustained benefit.
How to read the evidence
Rated strong: randomized, placebo-controlled phase 2 trial published in NEJM with biopsy-confirmed endpoints and robust statistical significance across doses.
When this study was published
Published in 2024 in the New England Journal of Medicine. Phase 3 trials are expected to follow.
The bigger picture
This trial demonstrates that combining two peptide hormone pathways (glucagon + GLP-1) may be superior to single-pathway approaches for liver disease. It represents the broader trend of multi-target peptide therapeutics and could reshape treatment of the growing MASH epidemic.
Questions still open
- Why did the highest dose (6.0 mg) show less improvement than the middle dose (4.8 mg)?
- How does survodutide compare head-to-head with GLP-1-only agonists like semaglutide for MASH?
- Will the fibrosis improvements translate to reduced liver-related clinical outcomes long-term?
Common questions
What is survodutide and how does it work?
Can survodutide cure fatty liver disease?
Read the original research
A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis.
The New England journal of medicine, 391(4), 311-319
Citation
Sanyal, Arun J; Bedossa, Pierre; Fraessdorf, Mandy; Neff, Guy W; Lawitz, Eric; Bugianesi, Elisabetta; Anstee, Quentin M; Hussain, Samina Ajaz; Newsome, Philip N; Ratziu, Vlad; Hosseini-Tabatabaei, Azadeh; Schattenberg, Jörn M; Noureddin, Mazen; Alkhouri, Naim; Younes, Ramy. (2024). A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis.. The New England journal of medicine, 391(4), 311-319. https://doi.org/10.1056/NEJMoa2401755